430 related articles for article (PubMed ID: 11581376)
41. Chemokine receptor-usage of clinical HIV-1 isolates obtained from patients with HIV-1 infection in late clinical stages using PHA-blast.
Matsuda S; Miyata M
Microbiol Immunol; 1999; 43(10):967-74. PubMed ID: 10585143
[TBL] [Abstract][Full Text] [Related]
42. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
43. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.
Mörner A; Björndal A; Albert J; Kewalramani VN; Littman DR; Inoue R; Thorstensson R; Fenyö EM; Björling E
J Virol; 1999 Mar; 73(3):2343-9. PubMed ID: 9971817
[TBL] [Abstract][Full Text] [Related]
44. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
Huang W; Eshleman SH; Toma J; Fransen S; Stawiski E; Paxinos EE; Whitcomb JM; Young AM; Donnell D; Mmiro F; Musoke P; Guay LA; Jackson JB; Parkin NT; Petropoulos CJ
J Virol; 2007 Aug; 81(15):7885-93. PubMed ID: 17507467
[TBL] [Abstract][Full Text] [Related]
45. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4.
Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M
Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179
[TBL] [Abstract][Full Text] [Related]
46. HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors.
Hoffman TL; Stephens EB; Narayan O; Doms RW
Proc Natl Acad Sci U S A; 1998 Sep; 95(19):11360-5. PubMed ID: 9736741
[TBL] [Abstract][Full Text] [Related]
47. Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.
Willey SJ; Reeves JD; Hudson R; Miyake K; Dejucq N; Schols D; De Clercq E; Bell J; McKnight A; Clapham PR
J Virol; 2003 Jun; 77(11):6138-52. PubMed ID: 12743271
[TBL] [Abstract][Full Text] [Related]
48. Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues.
Peters PJ; Dueñas-Decamp MJ; Sullivan WM; Clapham PR
J Neuroimmune Pharmacol; 2007 Mar; 2(1):32-41. PubMed ID: 18040824
[TBL] [Abstract][Full Text] [Related]
49. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
50. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
Pontow S; Ratner L
J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632
[TBL] [Abstract][Full Text] [Related]
51. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
52. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry.
Chen Z; Zhou P; Ho DD; Landau NR; Marx PA
J Virol; 1997 Apr; 71(4):2705-14. PubMed ID: 9060623
[TBL] [Abstract][Full Text] [Related]
53. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
Cho MW; Lee MK; Carney MC; Berson JF; Doms RW; Martin MA
J Virol; 1998 Mar; 72(3):2509-15. PubMed ID: 9499115
[TBL] [Abstract][Full Text] [Related]
54. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
Pastore C; Nedellec R; Ramos A; Pontow S; Ratner L; Mosier DE
J Virol; 2006 Jan; 80(2):750-8. PubMed ID: 16378977
[TBL] [Abstract][Full Text] [Related]
55. Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia.
Ghorpade A; Xia MQ; Hyman BT; Persidsky Y; Nukuna A; Bock P; Che M; Limoges J; Gendelman HE; Mackay CR
J Virol; 1998 Apr; 72(4):3351-61. PubMed ID: 9525662
[TBL] [Abstract][Full Text] [Related]
56. CXCR4 and CCR5 regulation and expression patterns on T- and monocyte-macrophage cell lineages: implications for susceptibility to infection by HIV-1.
Joly M; Pinto JM
Math Biosci; 2005 May; 195(1):92-126. PubMed ID: 15893340
[TBL] [Abstract][Full Text] [Related]
57. Stoichiometry for entry and binding properties of the Env protein of R5 T cell-tropic HIV-1 and its evolutionary variant of macrophage-tropic HIV-1.
Bonner X; Sondgeroth A; McCue A; Nicely N; Tripathy A; Spielvogel E; Moeser M; Ke R; Leiderman K; Joseph SB; Swanstrom R
mBio; 2024 Apr; 15(4):e0032124. PubMed ID: 38426750
[TBL] [Abstract][Full Text] [Related]
58. CD4 receptor-dependent entry of human immunodeficiency virus type-1 env-pseudotypes into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor.
Park IW; Koziel H; Hatch W; Li X; Du B; Groopman JE
Am J Respir Cell Mol Biol; 1999 May; 20(5):864-71. PubMed ID: 10226056
[TBL] [Abstract][Full Text] [Related]
59. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
Zhang Y; Lou B; Lal RB; Gettie A; Marx PA; Moore JP
J Virol; 2000 Aug; 74(15):6893-910. PubMed ID: 10888629
[TBL] [Abstract][Full Text] [Related]
60. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
